Nicolas Goossens

Summary

Affiliation: University Hospital
Country: Switzerland

Publications

  1. doi request reprint Peribiliary Gland Dilatation in Cirrhosis: Relationship with Liver Failure and Stem Cell/Proliferation Markers
    Nicolas Goossens
    Division of Gastroenterology and Hepatology, Geneva University Hospital, 4, rue Gabrielle Perret Gentil, 1211, Geneva 14, Switzerland
    Dig Dis Sci . 2016
  2. pmc Nonalcoholic Steatohepatitis Is Associated With Increased Mortality in Obese Patients Undergoing Bariatric Surgery
    Nicolas Goossens
    Division of Gastroenterology and Hepatology, University Hospital, Geneva, Switzerland Division of Liver Diseases, Department of Medicine, Liver Cancer Program, Tisch Cancer Institute, Mount Sinai Medical Center, New York, New York Electronic address
    Clin Gastroenterol Hepatol 14:1619-1628. 2016
  3. doi request reprint Severe immune-mediated drug-induced liver injury linked to ibandronate: a case report
    Nicolas Goossens
    Division of Gastroenterology and Hepatology, Geneva University Hospital, Geneva, Switzerland Electronic address
    J Hepatol 59:1139-42. 2013
  4. ncbi request reprint [Reactivation of hepatitis B associated with immunosuppression]
    N Goossens
    Service de gastroentérologie et hepatologie, Département des spécialités de médecine, HUG, 1211 Geneve 14
    Rev Med Suisse 9:1566, 1568-71. 2013
  5. ncbi request reprint [Alcoholic steatohepatitis: what's new in 2012?]
    N Goossens
    Service de gastroentérologie et hepatologie, Département des spécialités, HUG, Geneve
    Rev Med Suisse 8:1646-8, 1650-1. 2012
  6. ncbi request reprint [New treatments for hepatitis C, which targets, what timeline?]
    Nicolas Goossens
    Service de Gastroentérologie et d Hépatologie, Département des spécialités, HUG, 1211 Geneve 14
    Rev Med Suisse 7:1683-8. 2011
  7. doi request reprint Is genotype 3 of the hepatitis C virus the new villain?
    Nicolas Goossens
    Division of Gastroenterology and Hepatology, Geneva University Hospital, Geneva, Switzerland
    Hepatology 59:2403-12. 2014
  8. ncbi request reprint Liver volume is a prognostic indicator for clinical outcome of patients with alcoholic hepatitis
    Romain Breguet
    Department of Radiology, University Hospitals of Geneva, Rue Gabrielle Perret Gentil 4, 1211, Geneva 14, Switzerland
    Abdom Radiol (NY) . 2016
  9. pmc Molecular Liver Cancer Prevention in Cirrhosis by Organ Transcriptome Analysis and Lysophosphatidic Acid Pathway Inhibition
    Shigeki Nakagawa
    Division of Liver Diseases, Department of Medicine, Liver Cancer Program, Tisch Cancer Institute, Graduate School of Biomedical Sciences, Icahn School of Medicine at Mount Sinai, New York, NY 10029, USA Department of Gastroenterological Surgery, Graduate School of Medical Sciences, Kumamoto University, Kumamoto 860 8556, Japan
    Cancer Cell 30:879-890. 2016
  10. pmc Use of big data in drug development for precision medicine
    Rosa S Kim
    Division of Liver Diseases, Department of Medicine, Liver Cancer Program, Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, USA
    Expert Rev Precis Med Drug Dev 1:245-253. 2016

Collaborators

Detail Information

Publications23

  1. doi request reprint Peribiliary Gland Dilatation in Cirrhosis: Relationship with Liver Failure and Stem Cell/Proliferation Markers
    Nicolas Goossens
    Division of Gastroenterology and Hepatology, Geneva University Hospital, 4, rue Gabrielle Perret Gentil, 1211, Geneva 14, Switzerland
    Dig Dis Sci . 2016
    ..We aimed to identify clinical factors associated with dilated PBG and to perform a detailed morphometric assessment of dilated PBG in cirrhotic patients undergoing liver transplantation (LT)...
  2. pmc Nonalcoholic Steatohepatitis Is Associated With Increased Mortality in Obese Patients Undergoing Bariatric Surgery
    Nicolas Goossens
    Division of Gastroenterology and Hepatology, University Hospital, Geneva, Switzerland Division of Liver Diseases, Department of Medicine, Liver Cancer Program, Tisch Cancer Institute, Mount Sinai Medical Center, New York, New York Electronic address
    Clin Gastroenterol Hepatol 14:1619-1628. 2016
    ..We investigated the prognostic relevance of nonalcoholic steatohepatitis (NASH) and liver gene expression patterns in patients undergoing bariatric surgery...
  3. doi request reprint Severe immune-mediated drug-induced liver injury linked to ibandronate: a case report
    Nicolas Goossens
    Division of Gastroenterology and Hepatology, Geneva University Hospital, Geneva, Switzerland Electronic address
    J Hepatol 59:1139-42. 2013
    ..We report the first case of ibandronate-related hepatotoxicity and, to our knowledge, the first case of immune-mediated drug-induced liver injury (DILI) related to bisphosphonates. ..
  4. ncbi request reprint [Reactivation of hepatitis B associated with immunosuppression]
    N Goossens
    Service de gastroentérologie et hepatologie, Département des spécialités de médecine, HUG, 1211 Geneve 14
    Rev Med Suisse 9:1566, 1568-71. 2013
    ..In situations at high risk of viral reactivation prophylactic antiviral therapy is indicated and reduces morbidity and mortality related to viral hepatitis flares...
  5. ncbi request reprint [Alcoholic steatohepatitis: what's new in 2012?]
    N Goossens
    Service de gastroentérologie et hepatologie, Département des spécialités, HUG, Geneve
    Rev Med Suisse 8:1646-8, 1650-1. 2012
    ..In case of uncontrolled infection, pentoxifylline may be administered. The Lille score, measured at the 7th day of corticosteroid therapy, measures response to therapy and guides the total duration of treatment...
  6. ncbi request reprint [New treatments for hepatitis C, which targets, what timeline?]
    Nicolas Goossens
    Service de Gastroentérologie et d Hépatologie, Département des spécialités, HUG, 1211 Geneve 14
    Rev Med Suisse 7:1683-8. 2011
    ..However, these new molecules may lead to serious adverse effects and drug interactions with which the specialist and the primary care physician must be familiar...
  7. doi request reprint Is genotype 3 of the hepatitis C virus the new villain?
    Nicolas Goossens
    Division of Gastroenterology and Hepatology, Geneva University Hospital, Geneva, Switzerland
    Hepatology 59:2403-12. 2014
    ..In addition, increasing clinical and experimental data show that HCV genotype 3 may be associated not only with severe steatosis, but also with accelerated fibrosis progression rate and increased oncogenesis...
  8. ncbi request reprint Liver volume is a prognostic indicator for clinical outcome of patients with alcoholic hepatitis
    Romain Breguet
    Department of Radiology, University Hospitals of Geneva, Rue Gabrielle Perret Gentil 4, 1211, Geneva 14, Switzerland
    Abdom Radiol (NY) . 2016
    ..To evaluate the prognostic value of abdominal computed tomography (CT) in patients with alcoholic hepatitis (AH)...
  9. pmc Molecular Liver Cancer Prevention in Cirrhosis by Organ Transcriptome Analysis and Lysophosphatidic Acid Pathway Inhibition
    Shigeki Nakagawa
    Division of Liver Diseases, Department of Medicine, Liver Cancer Program, Tisch Cancer Institute, Graduate School of Biomedical Sciences, Icahn School of Medicine at Mount Sinai, New York, NY 10029, USA Department of Gastroenterological Surgery, Graduate School of Medical Sciences, Kumamoto University, Kumamoto 860 8556, Japan
    Cancer Cell 30:879-890. 2016
    ..These results demonstrate the utility of clinical organ transcriptome to enable a strategy, namely, reverse-engineering precision cancer prevention...
  10. pmc Use of big data in drug development for precision medicine
    Rosa S Kim
    Division of Liver Diseases, Department of Medicine, Liver Cancer Program, Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, USA
    Expert Rev Precis Med Drug Dev 1:245-253. 2016
    ..Here we overview currently available resources and discuss future prospects...
  11. pmc Molecular classification of hepatocellular carcinoma: potential therapeutic implications
    Nicolas Goossens
    Division of Liver Diseases, Department of Medicine, Liver Cancer Program, Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, 1470 Madison Ave, PO Box 1123, New York, NY 10029, USA Division of Gastroenterology and Hepatology, Geneva University Hospital, Geneva, Switzerland
    Hepat Oncol 2:371-379. 2015
    ..Molecular therapies selectively targeting features of the HCC subclasses have suggested their utility in enriching potential responders in clinical trials and guiding therapeutic decision-making for HCC patients...
  12. pmc Molecular prognostic prediction in liver cirrhosis
    Nicolas Goossens
    Nicolas Goossens, Shigeki Nakagawa, Yujin Hoshida, Division of Liver Diseases, Department of Medicine, Liver Cancer Program, Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, NY 10029, United States
    World J Gastroenterol 21:10262-73. 2015
    ....
  13. pmc Using Big Data to Discover Diagnostics and Therapeutics for Gastrointestinal and Liver Diseases
    Benjamin Wooden
    Division of Liver Diseases, Department of Medicine, Icahn School of Medicine at Mount Sinai, New York, New York
    Gastroenterology 152:53-67.e3. 2017
    ....
  14. pmc Clinicopathological indices to predict hepatocellular carcinoma molecular classification
    Poh Seng Tan
    Division of Liver Diseases, Department of Medicine, Liver Cancer Program, Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, NY, USA
    Liver Int 36:108-18. 2016
    ..We aimed to overcome these challenges by developing clinicopathological surrogate indices of HCC molecular classification...
  15. pmc A hepatic stellate cell gene expression signature associated with outcomes in hepatitis C cirrhosis and hepatocellular carcinoma after curative resection
    David Y Zhang
    Department of Medicine, Division of Liver Diseases, Icahn School of Medicine at Mount Sinai, New York, New York, USA
    Gut 65:1754-64. 2016
    ..We used an informatics approach to identify and validate genes whose expression is unique to hepatic stellate cells and assessed the prognostic capability of their expression in cirrhosis...
  16. pmc The XBP1 Arm of the Unfolded Protein Response Induces Fibrogenic Activity in Hepatic Stellate Cells Through Autophagy
    Rosa S Kim
    Division of Liver Diseases, Department of Medicine, Liver Cancer Program, Tisch Cancer Institute, Graduate School of Biomedical Sciences, Icahn School of Medicine at Mount Sinai, New York, US
    Sci Rep 6:39342. 2016
    ..Thus, XBP1-mediated UPR contributes to fibrogenic HSC activation and is functionally linked to cellular autophagy...
  17. doi request reprint The impact of obesity and metabolic syndrome on chronic hepatitis C
    Nicolas Goossens
    Division of Gastroenterology and Hepatology, Geneva University Hospital, 4 rue Gabrielle Perret Gentil, 1211 Geneva 4, Switzerland
    Clin Liver Dis 18:147-56. 2014
    ..Viral and metabolic steatosis and its interactions with HCV and the metabolic syndrome are discussed. Management and the need for further research conclude the article...
  18. pmc A capillary blood ammonia bedside test following glutamine load to improve the diagnosis of hepatic encephalopathy in cirrhosis
    Saskia Ditisheim
    Gastroenterology and Hepatology, University Hospitals and Faculty of Medicine, 4, rue Gabrielle Perret Gentil, 1211 Geneva, Switzerland
    BMC Gastroenterol 11:134. 2011
    ..Hepatic encephalopathy (HE) is a frequent and severe complication of cirrhosis. A single determination of ammonia in venous blood correlates poorly with neurological symptoms. Thus, a better biological marker is needed...
  19. pmc Drug Pricing Evolution in Hepatitis C
    Nathalie Vernaz
    Medical Direction, Geneva University Hospitals, University of Geneva, Geneva, Switzerland
    PLoS ONE 11:e0157098. 2016
    ....
  20. pmc Hepatitis C virus-induced hepatocellular carcinoma
    Nicolas Goossens
    Division of Liver Diseases, Department of Medicine, Liver Cancer Program, Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, USA Division of Gastroenterology and Hepatology, Geneva University Hospital, Geneva, Switzerland
    Clin Mol Hepatol 21:105-14. 2015
    ..Another role for molecular biomarker-based stratification could be enrichment of HCC chemoprevention clinical trials leading to smaller sample size, shorter trial duration, and reduced costs. ..
  21. ncbi request reprint Insulin resistance, non-alcoholic fatty liver disease and hepatitis C virus infection
    Nicolas Goossens
    Divisions of Clinical Pathology and of Gastroenterology and Hepatology, Geneva University Hospital, 4 rue Gabrielle Perret Gentil, 1211 Geneva 4, Switzerland
    Rev Recent Clin Trials 9:204-9. 2014
    ..We conclude by discussing a possible increased incidence of cardiovascular events in HCV patients. ..
  22. doi request reprint IL28B alleles associated with poor hepatitis C virus (HCV) clearance protect against inflammation and fibrosis in patients infected with non-1 HCV genotypes
    Pierre Yves Bochud
    Service of Infectious Diseases, Department of Medicine, University Hospital and University of Lausanne, Lausanne, Switzerland
    Hepatology 55:384-94. 2012
    ..48 (95% confidence intervals 0.30-0.78) and 0.56 (0.35-0.92), respectively. IL28B polymorphisms were not predictive of the development of hepatocellular carcinoma...
  23. pmc DOME/GALT type adenocarcimoma of the colon: a case report, literature review and a unified phenotypic categorization
    Hala Kannuna
    Department of Clinical Pathology, Geneva University Hospital, 1 rue Michel Servet, 1211, Geneva, Switzerland
    Diagn Pathol 10:92. 2015
    ..The two variants might therefore be grouped into a unified category...